PL1673352T3 - Sulfoksyiminopodstawione pirymidyny jako inhibitory CDK i/lub VEGF, ich wytwarzanie i zastosowanie jako środków leczniczych - Google Patents

Sulfoksyiminopodstawione pirymidyny jako inhibitory CDK i/lub VEGF, ich wytwarzanie i zastosowanie jako środków leczniczych

Info

Publication number: PL1673352T3
Authority: PL; Poland
Prior art keywords: sulfoximine; vegf; inhibitors; drugs; production
Prior art date: 2003-10-16

Application number

PL04790500T

Other languages

English (en)

Inventor

Ulrich Lücking

Martin Krüger

Rolf Jautelat

Gerhard Siemeister

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-16

Filing date

2004-10-12

Publication date

2009-09-30

2004-10-12 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2009-09-30 Publication of PL1673352T3 publication Critical patent/PL1673352T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Ophthalmology & Optometry (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)

PL04790500T 2003-10-16 2004-10-12 Sulfoksyiminopodstawione pirymidyny jako inhibitory CDK i/lub VEGF, ich wytwarzanie i zastosowanie jako środków leczniczych PL1673352T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10349423A DE10349423A1 (de)	2003-10-16	2003-10-16	Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
PCT/EP2004/011661 WO2005037800A1 (de)	2003-10-16	2004-10-12	Sulfoximinsubstituierte pyrimidine als cdk- und/oder vegf-inhibitoren, deren herstellung und verwendung als arzneimittel
EP04790500A EP1673352B1 (de)	2003-10-16	2004-10-12	Sulfoximinsubstituierte pyrimidine als cdk- und/oder vegf-inhitoren, deren herstellung und verwendung als arzneimittel

Publications (1)

Publication Number	Publication Date
PL1673352T3 true PL1673352T3 (pl)	2009-09-30

Family

ID=34442222

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04790500T PL1673352T3 (pl)	2003-10-16	2004-10-12	Sulfoksyiminopodstawione pirymidyny jako inhibitory CDK i/lub VEGF, ich wytwarzanie i zastosowanie jako środków leczniczych

Country Status (35)

Country	Link
US (2)	US8507510B2 (pl)
EP (1)	EP1673352B1 (pl)
JP (1)	JP4700006B2 (pl)
KR (1)	KR101117387B1 (pl)
CN (1)	CN1867553B (pl)
AR (1)	AR046119A1 (pl)
AT (1)	ATE427939T1 (pl)
AU (1)	AU2004281960B2 (pl)
BR (1)	BRPI0415421A (pl)
CA (1)	CA2542492C (pl)
CR (1)	CR8363A (pl)
CY (1)	CY1110058T1 (pl)
DE (2)	DE10349423A1 (pl)
DK (1)	DK1673352T3 (pl)
EC (1)	ECSP066568A (pl)
ES (1)	ES2324475T3 (pl)
GT (1)	GT200400206A (pl)
HR (1)	HRP20090348T1 (pl)
IL (1)	IL174952A (pl)
JO (1)	JO2534B1 (pl)
ME (1)	ME00158B (pl)
MX (1)	MXPA06004091A (pl)
MY (1)	MY140291A (pl)
NO (1)	NO337290B1 (pl)
NZ (1)	NZ546510A (pl)
PE (1)	PE20050907A1 (pl)
PL (1)	PL1673352T3 (pl)
PT (1)	PT1673352E (pl)
RS (1)	RS51657B (pl)
RU (1)	RU2410378C2 (pl)
SI (1)	SI1673352T1 (pl)
TW (1)	TWI347844B (pl)
UA (1)	UA86041C2 (pl)
WO (1)	WO2005037800A1 (pl)
ZA (1)	ZA200603885B (pl)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL159120A0 (en) *	2001-05-29	2004-05-12	Schering Ag	Cdk inhibiting pyrimidines, production thereof and their use as medicaments
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0205693D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
GB0205690D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
JP2005524672A (ja)	2002-03-09	2005-08-18	アストラゼネカアクチボラグ	Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体
GB0205688D0 (en)	2002-03-09	2002-04-24	Astrazeneca Ab	Chemical compounds
CN103169708B (zh)	2002-07-29	2018-02-02	里格尔药品股份有限公司	用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
US7157455B2 (en)	2003-02-10	2007-01-02	Hoffmann-La Roche Inc.	4-Aminopyrimidine-5-one derivatives
GB0311276D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
GB0311274D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
US7122542B2 (en)	2003-07-30	2006-10-17	Rigel Pharmaceuticals, Inc.	Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
DE10349423A1 (de) *	2003-10-16	2005-06-16	Schering Ag	Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7915443B2 (en)	2006-11-16	2011-03-29	Allergan, Inc.	Sulfoximines as kinase inhibitors
JP4812763B2 (ja)	2004-05-18	2011-11-09	ライジェルファーマシューティカルズ，インコーポレイテッド	シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
GB2420559B (en)	2004-11-15	2008-08-06	Rigel Pharmaceuticals Inc	Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US7449458B2 (en)	2005-01-19	2008-11-11	Rigel Pharmaceuticals, Inc.	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1705177A1 (en) *	2005-03-23	2006-09-27	Schering Aktiengesellschaft	N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
EP1710246A1 (en) *	2005-04-08	2006-10-11	Schering Aktiengesellschaft	Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
RU2485106C2 (ru)	2005-06-08	2013-06-20	Райджел Фамэсьютикэлз, Инк.	Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
CA2620333A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
US7745428B2 (en)	2005-09-30	2010-06-29	Astrazeneca Ab	Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US7705009B2 (en)	2005-11-22	2010-04-27	Hoffman-La Roche Inc.	4-aminopyrimidine-5-thione derivatives
FR2894746B1 (fr) *	2005-12-09	2008-06-13	Ipanema Technologies Sa	Procede et dispositif de controle a distance de la congestion de flux mailles dans un reseau de telecommunication en mode paquet
DE102005062742A1 (de) *	2005-12-22	2007-06-28	Bayer Schering Pharma Ag	Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP1803723A1 (de)	2006-01-03	2007-07-04	Bayer Schering Pharma Aktiengesellschaft	(2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
US8962643B2 (en)	2006-02-24	2015-02-24	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2382975A3 (en)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
DE102006027156A1 (de) *	2006-06-08	2007-12-13	Bayer Schering Pharma Ag	Sulfimide als Proteinkinaseinhibitoren
EP1878726A1 (en) *	2006-07-12	2008-01-16	Bayer Schering Pharma Aktiengesellschaft	Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
DE102006041382A1 (de) *	2006-08-29	2008-03-20	Bayer Schering Pharma Ag	Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
CA2673125C (en)	2006-10-19	2015-04-21	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US8558002B2 (en) *	2006-11-16	2013-10-15	Allergan, Inc.	Sulfoximines as kinase inhibitors
US8143410B2 (en)	2006-11-16	2012-03-27	Allergan, Inc.	Kinase inhibitors
EP2022785A1 (en) *	2007-06-20	2009-02-11	Bayer Schering Pharma Aktiengesellschaft	Alkynylpyrimidines as Tie2 kinase inhibitors
ES2385118T3 (es) *	2008-01-17	2012-07-18	Bayer Pharma Aktiengesellschaft	Derivados de quinazolina sustituida con sulfoximina como inmunomoduladores, su preparación y uso como medicamentos
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
PT2323993E (pt)	2008-04-16	2015-10-12	Portola Pharm Inc	2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
KR20100132550A (ko)	2008-04-16	2010-12-17	포톨라 파마슈티컬스, 인코포레이티드	ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
US8258144B2 (en)	2008-04-22	2012-09-04	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
EP2161259A1 (de) *	2008-09-03	2010-03-10	Bayer CropScience AG	4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
EP2179991A1 (de) *	2008-10-21	2010-04-28	Bayer Schering Pharma Aktiengesellschaft	Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179992A1 (de) *	2008-10-21	2010-04-28	Bayer Schering Pharma Aktiengesellschaft	Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179993A1 (de)	2008-10-21	2010-04-28	Bayer Schering Pharma Aktiengesellschaft	Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
DE102009001438A1 (de)	2009-03-10	2010-09-16	Bayer Schering Pharma Aktiengesellschaft	Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102009015070A1 (de)	2009-03-30	2010-10-14	Bayer Schering Pharma Aktiengesellschaft	Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
CA2768543C (en) *	2009-07-28	2017-06-20	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
DE102010014426A1 (de) *	2010-04-01	2011-10-06	Bayer Schering Pharma Aktiengesellschaft	Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014427A1 (de)	2010-04-01	2011-10-06	Bayer Schering Pharma Aktiengesellschaft	Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
MX2012014158A (es)	2010-06-04	2013-02-07	Hoffmann La Roche	Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
DE102010046720A1 (de)	2010-09-23	2012-03-29	Bayer Schering Pharma Aktiengesellschaft	Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
US20130317029A1 (en)	2010-11-01	2013-11-28	Portola Pharmaceuticals, Inc.	Oxypyrimidines as syk modulators
CA2816219C (en)	2010-11-01	2019-10-29	Portola Pharmaceuticals, Inc.	Nicotinamides as syk modulators
EP2975027A1 (en)	2010-11-01	2016-01-20	Portola Pharmaceuticals, Inc.	Nicotinamides as jak kinase modulators
ES2653967T3 (es)	2010-11-10	2018-02-09	Genentech, Inc.	Derivados de pirazol aminopirimidina como moduladores de LRRK2
TWI555737B (zh)	2011-05-24	2016-11-01	拜耳知識產權公司	含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2527332A1 (en)	2011-05-24	2012-11-28	Bayer Intellectual Property GmbH	4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
EP2755948B1 (en)	2011-09-16	2016-05-25	Bayer Intellectual Property GmbH	Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
CN103814029B (zh)	2011-09-23	2016-10-12	拜耳知识产权有限责任公司	取代的咪唑并哒嗪
US9498471B2 (en)	2011-10-20	2016-11-22	The Regents Of The University Of California	Use of CDK9 inhibitors to reduce cartilage degradation
US8877760B2 (en)	2011-11-23	2014-11-04	Portola Pharmaceuticals, Inc.	Substituted pyrazine-2-carboxamide kinase inhibitors
KR20140135215A (ko)	2012-03-21	2014-11-25	바이엘 인텔렉쳐 프로퍼티 게엠베하	특정한 종양의 치료를 위한 (rs)-s-시클로프로필-s-(4-｛[4-｛[(1r, 2r)-2-히드록시-1-메틸프로필]옥시｝-5-(트리플루오로메틸)피리미딘-2-일]아미노｝페닐)술폭시미드의 용도
EP2903970A4 (en)	2012-10-08	2016-11-30	Portola Pharm Inc	SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
ES2616441T3 (es)	2012-10-18	2017-06-13	Bayer Pharma Aktiengesellschaft	Derivados de N-(piridin-2-il))pirimidin-4-amina que contienen un grupo sulfona
HK1209414A1 (en)	2012-10-18	2016-04-01	Bayer Pharma Aktiengesellschaft	5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
US9499492B2 (en) *	2012-11-15	2016-11-22	Bayer Pharma Aktiengesellschaft	4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group
TW201418243A (zh) *	2012-11-15	2014-05-16	Bayer Pharma AG	含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
AU2013346939B2 (en)	2012-11-15	2017-06-08	Bayer Pharma Aktiengesellschaft	5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
WO2014173815A1 (en)	2013-04-23	2014-10-30	Bayer Pharma Aktiengesellschaft	Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
JP2016522231A (ja)	2013-06-21	2016-07-28	バイエルファーマアクチエンゲゼルシャフト	ジアミノヘテロアリール置換ピラゾール類
ES2630115T3 (es)	2013-07-04	2017-08-18	Bayer Pharma Aktiengesellschaft	Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina con sulfoximina sustituida y su uso como inhibidores de quinasa cdk9
WO2015063003A1 (en)	2013-10-30	2015-05-07	Bayer Pharma Aktiengesellschaft	Heteroaryl substituted pyrazoles
EP3080105B1 (en) *	2013-12-12	2020-09-02	Allergan, Inc.	Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors
EP3116869A1 (en)	2014-03-13	2017-01-18	Bayer Pharma Aktiengesellschaft	5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
CN106414412B (zh)	2014-04-01	2019-06-21	拜耳医药股份有限公司	含有磺酰二亚胺基团的二取代的5-氟嘧啶衍生物
CR20160471A (es)	2014-04-11	2016-12-21	Bayer Pharma AG	Compuestos novedosos macrocíclicos
TWI700283B (zh)	2014-08-04	2020-08-01	德商拜耳製藥公司	２-(嗎啉-４-基)-１,７-萘啶
CA3000633C (en)	2014-10-14	2023-10-03	The Regents Of The University Of California	Use of cdk9 and brd4 inhibitors to inhibit inflammation
CA2964696C (en)	2014-10-16	2022-09-06	Bayer Pharma Aktiengesellschaft	Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
CA2964683A1 (en)	2014-10-16	2016-04-21	Bayer Pharma Aktiengesellschaft	Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group
CA2999931A1 (en)	2015-09-29	2017-04-06	Bayer Pharma Aktiengesellschaft	Novel macrocyclic sulfondiimine compounds
JP6888000B2 (ja)	2015-10-08	2021-06-16	バイエルファーマアクチエンゲゼルシャフト	新規な修飾された大環状化合物
WO2017060322A2 (en)	2015-10-10	2017-04-13	Bayer Pharma Aktiengesellschaft	Ptefb-inhibitor-adc
ES2900199T3 (es)	2017-03-28	2022-03-16	Bayer Ag	Novedosos compuestos macrocíclicos inhibidores de PTEFB
EP3601236A1 (en)	2017-03-28	2020-02-05	Bayer Aktiengesellschaft	Novel ptefb inhibiting macrocyclic compounds
KR101936054B1 (ko)	2017-06-23	2019-01-11	한국과학기술연구원	항염증 활성을 가지는 6-페녹시피리미딘 유도체, 이의 제조방법 및 이를 활성성분으로 하는 약학 조성물
US11701347B2 (en)	2018-02-13	2023-07-18	Bayer Aktiengesellschaft	Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
BR112021011894A2 (pt)	2018-12-21	2021-09-08	Daiichi Sankyo Company, Limited	Composição farmacêutica
WO2022266394A1 (en) *	2021-06-18	2022-12-22	The Trustees Of Columbia University In The City Of New York	Novel isomerohydrolase inhibitor for treatment of atrophic form of age-related macular degeneration and stargardt disease
IL322686A (en)	2023-02-16	2025-10-01	Gasherbrum Bio Inc	Heterocyclic glp-1 agonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5187189A (en) *	1991-01-22	1993-02-16	American Home Products Corporation	S-aminoalkyl-s-arylsulfoximines as antiarrhythmic agents
US5902817A (en) *	1997-04-09	1999-05-11	Guilford Pharmaceuticals Inc.	Certain sulfoxide and sulfone derivatives
GB9705361D0 (en) *	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
JP2000232898A (ja) *	1999-02-17	2000-08-29	Kyowa Medex Co Ltd	物質の定量方法および定量試薬
GB9905075D0 (en) *	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
GB0004888D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
WO2002009688A1 (en) *	2000-08-02	2002-02-07	Smithkline Beecham Corporation	Fatty acid synthase inhibitors
IL159120A0 (en) *	2001-05-29	2004-05-12	Schering Ag	Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) *	2001-05-30	2001-07-18	Astrazeneca Ab	Chemical compounds
EP1483260A1 (de) *	2002-03-11	2004-12-08	Schering Aktiengesellschaft	Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
US7288547B2 (en)	2002-03-11	2007-10-30	Schering Ag	CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
MXPA06002608A (es)	2002-12-20	2007-01-23	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
WO2005035951A1 (en)	2003-10-08	2005-04-21	The Lubrizol Corporation	System containing oxygen enriched diesel particulate filter and method thereof
DE10349423A1 (de) *	2003-10-16	2005-06-16	Schering Ag	Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

2003
- 2003-10-16 DE DE10349423A patent/DE10349423A1/de not_active Ceased
2004
- 2004-09-30 JO JO2004138A patent/JO2534B1/en active
- 2004-10-12 JP JP2006534714A patent/JP4700006B2/ja not_active Expired - Fee Related
- 2004-10-12 AT AT04790500T patent/ATE427939T1/de active
- 2004-10-12 HR HR20090348T patent/HRP20090348T1/hr unknown
- 2004-10-12 RU RU2006116466/04A patent/RU2410378C2/ru not_active IP Right Cessation
- 2004-10-12 CN CN2004800304726A patent/CN1867553B/zh not_active Expired - Fee Related
- 2004-10-12 PL PL04790500T patent/PL1673352T3/pl unknown
- 2004-10-12 DK DK04790500T patent/DK1673352T3/da active
- 2004-10-12 US US12/095,947 patent/US8507510B2/en not_active Expired - Fee Related
- 2004-10-12 WO PCT/EP2004/011661 patent/WO2005037800A1/de not_active Ceased
- 2004-10-12 MX MXPA06004091A patent/MXPA06004091A/es active IP Right Grant
- 2004-10-12 ES ES04790500T patent/ES2324475T3/es not_active Expired - Lifetime
- 2004-10-12 AU AU2004281960A patent/AU2004281960B2/en not_active Ceased
- 2004-10-12 RS YU20060264A patent/RS51657B/sr unknown
- 2004-10-12 SI SI200431148T patent/SI1673352T1/sl unknown
- 2004-10-12 PT PT04790500T patent/PT1673352E/pt unknown
- 2004-10-12 DE DE502004009330T patent/DE502004009330D1/de not_active Expired - Lifetime
- 2004-10-12 NZ NZ546510A patent/NZ546510A/en not_active IP Right Cessation
- 2004-10-12 UA UAA200605171A patent/UA86041C2/uk unknown
- 2004-10-12 EP EP04790500A patent/EP1673352B1/de not_active Expired - Lifetime
- 2004-10-12 CA CA2542492A patent/CA2542492C/en not_active Expired - Fee Related
- 2004-10-12 ME MEP-2008-158A patent/ME00158B/me unknown
- 2004-10-12 BR BRPI0415421-5A patent/BRPI0415421A/pt active Search and Examination
- 2004-10-13 TW TW093130948A patent/TWI347844B/zh not_active IP Right Cessation
- 2004-10-13 GT GT200400206A patent/GT200400206A/es unknown
- 2004-10-15 PE PE2004001003A patent/PE20050907A1/es not_active Application Discontinuation
- 2004-10-15 MY MYPI20044268A patent/MY140291A/en unknown
- 2004-10-15 AR ARP040103755A patent/AR046119A1/es unknown
- 2004-10-18 US US10/966,098 patent/US7338958B2/en not_active Expired - Fee Related
2006
- 2006-04-11 IL IL174952A patent/IL174952A/en not_active IP Right Cessation
- 2006-04-25 CR CR8363A patent/CR8363A/es unknown
- 2006-05-12 EC EC2006006568A patent/ECSP066568A/es unknown
- 2006-05-15 ZA ZA200603885A patent/ZA200603885B/en unknown
- 2006-05-15 KR KR1020067009424A patent/KR101117387B1/ko not_active Expired - Fee Related
- 2006-05-15 NO NO20062174A patent/NO337290B1/no not_active IP Right Cessation
2009
- 2009-07-08 CY CY20091100726T patent/CY1110058T1/el unknown

Also Published As

Publication number	Publication date
ECSP066568A (es)	2006-10-17
ATE427939T1 (de)	2009-04-15
AU2004281960B2 (en)	2010-07-01
IL174952A (en)	2011-02-28
MY140291A (en)	2009-12-31
EP1673352A1 (de)	2006-06-28
HRP20090348T1 (hr)	2009-09-30
UA86041C2 (uk)	2009-03-25
US7338958B2 (en)	2008-03-04
HK1093731A1 (en)	2007-03-09
ME00158B (me)	2010-10-10
JP2007508354A (ja)	2007-04-05
SI1673352T1 (sl)	2009-08-31
CN1867553B (zh)	2011-06-08
JO2534B1 (en)	2010-09-05
WO2005037800A1 (de)	2005-04-28
NO20062174L (no)	2006-07-14
ZA200603885B (en)	2007-09-26
DK1673352T3 (da)	2009-07-06
US8507510B2 (en)	2013-08-13
EP1673352B1 (de)	2009-04-08
TWI347844B (en)	2011-09-01
TW200524613A (en)	2005-08-01
US20100076000A1 (en)	2010-03-25
BRPI0415421A (pt)	2006-12-05
KR20060122860A (ko)	2006-11-30
MXPA06004091A (es)	2006-06-27
PT1673352E (pt)	2009-06-19
CN1867553A (zh)	2006-11-22
US20050176743A1 (en)	2005-08-11
CY1110058T1 (el)	2015-01-14
AR046119A1 (es)	2005-11-23
ES2324475T3 (es)	2009-08-07
RS20060264A (sr)	2008-06-05
PE20050907A1 (es)	2005-11-02
KR101117387B1 (ko)	2012-03-07
CA2542492C (en)	2013-12-31
NO337290B1 (no)	2016-02-29
DE10349423A1 (de)	2005-06-16
IL174952A0 (en)	2006-08-20
JP4700006B2 (ja)	2011-06-15
RS51657B (sr)	2011-10-31
RU2410378C2 (ru)	2011-01-27
NZ546510A (en)	2009-09-25
CR8363A (es)	2006-12-07
GT200400206A (es)	2005-10-06
MEP15808A (en)	2010-06-10
CA2542492A1 (en)	2005-04-28
RU2006116466A (ru)	2007-11-27
AU2004281960A1 (en)	2005-04-28
DE502004009330D1 (de)	2009-05-20

Publication	Publication Date	Title
SI1673352T1 (sl)	2009-08-31	Sulfoksiminsko substituirani pirimidini kot CDK-in/ali VEGF-inhibitorji, njihova priprava in uporaba kot zdravila
IL168102A0 (en)	2009-02-11	Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
EG25011A (en)	2011-05-25	Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments.
TWI347201B (en)	2011-08-21	Pharmaceutical products,uses thereof and methods for preparing the same
IL173204A0 (en)	2006-06-11	Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments
AU2003293757A1 (en)	2004-06-23	Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments
IL180874A0 (en)	2007-07-04	Substituted, bicyclic 8-pyrrolidinoxanthines, method for the production thereof and their use as medicaments
IL181012A0 (en)	2007-07-04	Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments
IL178334A0 (en)	2007-02-11	Selected cgrp antagonists, methods for the production thereof and their use as medicaments
PL378168A1 (pl)	2006-03-06	Dihydropterydynony, sposoby ich wytwarzania i ich zastosowanie w postaci leków
IL190423A0 (en)	2008-11-03	Selected cgrp antagonists , methods for the production thereof and their use as medicaments
IL174405A0 (en)	2006-08-01	1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics
IL189497A0 (en)	2008-08-07	Selected cgrp antagonists, methods for the production thereof and their use as medicaments
IL183395A0 (en)	2007-09-20	Meta-substituted thiazolidinones, the production thereof and their use as medicaments
PL394604A1 (pl)	2011-07-18	Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna
IL175245A0 (en)	2006-09-05	Thiozolidinones, production and use thereof as medicaments
IL169318A0 (en)	2009-02-11	Pyrimidines, methods for the production thereof, and use thereof
IL174975A0 (en)	2006-08-20	2-phenyl-benzofuran derivatives, method for the production thereof and their use
ZA200705782B (en)	2009-09-30	Meta-substituted thiazolidinones, the production thereof and their use as medicaments
PL363320A1 (pl)	2004-11-15	Pochodne kaloporozydu, sposób ich wytwarzania i ich zastosowanie
IL173447A0 (en)	2006-06-11	Substituted benzoylureido-o-benzoylamides, method for the production thereof and use of the same
EP1829860A4 (en)	2011-06-08	9,10-SECOPREGNANDERIVAT AND MEDICINE
AU2003216893A1 (en)	2003-10-13	Phenethylacrylamide, methods for the production thereof and agents containing the same
GB0315201D0 (en)	2003-08-06	Substituted organopolysiloxanes, methods for the production and use thereof
HK1113133A (en)	2008-09-26	Substituted oxindol derivatives, drugs containing said derivatives and the use thereof